BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

649 related articles for article (PubMed ID: 21876084)

  • 21. Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy.
    Liersch T; Langer C; Ghadimi BM; Kulle B; Aust DE; Baretton GB; Schwabe W; Häusler P; Becker H; Jakob C
    J Clin Oncol; 2006 Sep; 24(25):4062-8. PubMed ID: 16943523
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Can histopathologic assessment of circumferential margin after preoperative pelvic chemoradiotherapy for T3-T4 rectal cancer predict for 3-year disease-free survival?
    Mawdsley S; Glynne-Jones R; Grainger J; Richman P; Makris A; Harrison M; Ashford R; Harrison RA; Osborne M; Livingstone JI; MacDonald P; Mitchell IC; Meyrick-Thomas J; Northover JM; Windsor A; Novell R; Wallace M
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):745-52. PubMed ID: 16199310
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Histologic response after neoadjuvant therapy in rectal adenocarcinoma: own experience and review of the literature].
    Mátrai Z; Lövey J; Hitre E; Orosz Z; Gödény M; Péley G; Sulyok Z; Rényi Vámos F; Farkas E; Köves I
    Orv Hetil; 2006 Oct; 147(42):2011-20. PubMed ID: 17165600
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outcomes of clinical T4M0 extra-peritoneal rectal cancer treated with preoperative radiochemotherapy and surgery: a prospective evaluation of a single institutional experience.
    Valentini V; Coco C; Rizzo G; Manno A; Crucitti A; Mattana C; Ratto C; Verbo A; Vecchio FM; Barbaro B; Gambacorta MA; Montoro C; Barba MC; Sofo L; Papa V; Menghi R; D'Ugo DM; Doglietto G
    Surgery; 2009 May; 145(5):486-94. PubMed ID: 19375606
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical and pathologic predictors of locoregional recurrence, distant metastasis, and overall survival in patients treated with chemoradiation and mesorectal excision for rectal cancer.
    Das P; Skibber JM; Rodriguez-Bigas MA; Feig BW; Chang GJ; Hoff PM; Eng C; Wolff RA; Janjan NA; Delclos ME; Krishnan S; Levy LB; Ellis LM; Crane CH
    Am J Clin Oncol; 2006 Jun; 29(3):219-24. PubMed ID: 16755173
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictors of disease-free survival in rectal cancer patients undergoing curative proctectomy.
    Stewart D; Yan Y; Mutch M; Kodner I; Hunt S; Lowney J; Birnbaum E; Read T; Fleshman J; Dietz D
    Colorectal Dis; 2008 Nov; 10(9):879-86. PubMed ID: 19037929
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pathologic stage is most prognostic of disease-free survival in locally advanced rectal cancer patients after preoperative chemoradiation.
    Quah HM; Chou JF; Gonen M; Shia J; Schrag D; Saltz LB; Goodman KA; Minsky BD; Wong WD; Weiser MR
    Cancer; 2008 Jul; 113(1):57-64. PubMed ID: 18442099
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modern multidisciplinary treatment of rectal cancer based on staging with magnetic resonance imaging leads to excellent local control, but distant control remains a challenge.
    Engelen SM; Maas M; Lahaye MJ; Leijtens JW; van Berlo CL; Jansen RL; Breukink SO; Dejong CH; van de Velde CJ; Beets-Tan RG; Beets GL
    Eur J Cancer; 2013 Jul; 49(10):2311-20. PubMed ID: 23571146
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Extended total mesorectal excision in locally advanced rectal cancer (T4a) and the clinical role of MRI-evaluated neo-adjuvant downstaging.
    Larsen SG; Wiig JN; Emblemsvaag HL; Grøholt KK; Hole KH; Bentsen A; Dueland S; Vetrhus T; Giercksky KE
    Colorectal Dis; 2009 Sep; 11(7):759-67. PubMed ID: 18662240
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MRI assessment and outcomes in patients receiving neoadjuvant chemotherapy only for primary rectal cancer: long-term results from the GEMCAD 0801 trial.
    Patel UB; Brown G; Machado I; Santos-Cores J; Pericay C; Ballesteros E; Salud A; Isabel-Gil M; Montagut C; Maurel J; Ramón-Ayuso J; Martin N; Estevan R; Fernandez-Martos C
    Ann Oncol; 2017 Feb; 28(2):344-353. PubMed ID: 28426108
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk factors for adverse outcome in patients with rectal cancer treated with an abdominoperineal resection in the total mesorectal excision trial.
    den Dulk M; Marijnen CA; Putter H; Rutten HJ; Beets GL; Wiggers T; Nagtegaal ID; van de Velde CJ
    Ann Surg; 2007 Jul; 246(1):83-90. PubMed ID: 17592295
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The correlation between tumour regression grade and lymph node status after chemoradiation in rectal cancer.
    Berho M; Oviedo M; Stone E; Chen C; Nogueras J; Weiss E; Sands D; Wexner S
    Colorectal Dis; 2009 Mar; 11(3):254-8. PubMed ID: 18513188
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Magnetic resonance imaging accuracy in assessing tumour down-staging following chemoradiation in rectal cancer.
    Suppiah A; Hunter IA; Cowley J; Garimella V; Cast J; Hartley JE; Monson JR
    Colorectal Dis; 2009 Mar; 11(3):249-53. PubMed ID: 18513192
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumor volume reduction rate measured by magnetic resonance volumetry correlated with pathologic tumor response of preoperative chemoradiotherapy for rectal cancer.
    Yeo SG; Kim DY; Kim TH; Jung KH; Hong YS; Chang HJ; Park JW; Lim SB; Choi HS; Jeong SY
    Int J Radiat Oncol Biol Phys; 2010 Sep; 78(1):164-71. PubMed ID: 20004532
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Accuracy of MRI for predicting the circumferential resection margin, mesorectal fascia invasion, and tumor response to neoadjuvant chemoradiotherapy for locally advanced rectal cancer.
    Kim SH; Lee JM; Park HS; Eun HW; Han JK; Choi BI
    J Magn Reson Imaging; 2009 May; 29(5):1093-101. PubMed ID: 19388124
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efforts to improve local control in rectal cancer compromise survival by the potential morbidity of optimal mesorectal excision.
    Laurent C; Nobili S; Rullier A; Vendrely V; Saric J; Rullier E
    J Am Coll Surg; 2006 Nov; 203(5):684-91. PubMed ID: 17084330
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An interval >7 weeks between neoadjuvant therapy and surgery improves pathologic complete response and disease-free survival in patients with locally advanced rectal cancer.
    Tulchinsky H; Shmueli E; Figer A; Klausner JM; Rabau M
    Ann Surg Oncol; 2008 Oct; 15(10):2661-7. PubMed ID: 18389322
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Magnetic resonance imaging defined mucinous rectal carcinoma is an independent imaging biomarker for poor prognosis and poor response to preoperative chemoradiotherapy.
    Yu SK; Chand M; Tait DM; Brown G
    Eur J Cancer; 2014 Mar; 50(5):920-7. PubMed ID: 24440086
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chemoradiotherapy followed by surgery in rectal cancer: improved local control using a moderately high pelvic radiation dose.
    Lee SH; Lee KC; Choi JH; Oh JH; Baek JH; Park SH; Shin DB
    Jpn J Clin Oncol; 2008 Feb; 38(2):112-21. PubMed ID: 18263881
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The optimult study concept - selective neoadjuvant chemoradiation therapy based on preoperative MRI].
    Kreis ME; Junginger T; Rödel C; Heinemann V; Nikolaou K; Mansmann U; Jauch KW
    Zentralbl Chir; 2010 Aug; 135(4):302-6. PubMed ID: 20806131
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.